Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice.

Polymorphisms in the transcription factor Stat4 gene have been implicated as risk factors for systemic lupus erythematosus. Although some polymorphisms have a strong association with autoantibodies and nephritis, their impact on pathophysiology is still unknown. To explore this further we used signal transducers and activators of transcription 4 (Stat4) knockout MRL/MpJ-Fas(lpr)/Fas(lpr) (MRL-Fas(lpr)) mice and found that they did not differ in survival or renal function from Stat4-intact MRL-Fas(lpr) mice. Circulating interleukin (IL)-18 levels, however, were elevated in Stat4-deficient compared to Stat4-intact mice, suggesting that this interleukin might contribute to the progression of lupus nephritis independent of Stat4. In a second approach, Stat4 antisense or missense oligonucleotides or vehicle were given to MRL-Fas(lpr) mice with advanced nephritis. Each of these treatments temporarily ameliorated disease, although IL-18 was increased in each setting. Based on these findings, studies using gene transfer to overexpress IL-18 in MRL-Fas(lpr) and IL-12p40/IL-23 knockout MRL-Fas(lpr) mice reveal a critical role for IL-18 in mediating disease. Thus, the Stat4 and IL-12 (an activator of Stat4)-independent factor, IL-18, can drive autoimmune lupus nephritis in MRL-Fas(lpr) mice. Temporarily blocking Stat4 during advanced nephritis ameliorates disease, suggesting a time-dependent compensatory proinflammatory mechanism.

[1]  M. Kaplan,et al.  Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice , 1996, Nature.

[2]  P. Schirmacher,et al.  Targeting of the Transcription Factor STAT4 by Antisense Phosphorothioate Oligonucleotides Suppresses Collagen-Induced Arthritis1 , 2007, The Journal of Immunology.

[3]  M. Kurimoto,et al.  IL-18 Has IL-12-Independent Effects in Delayed-Type Hypersensitivity: Studies in Cell-Mediated Crescentic Glomerulonephritis1 , 2000, The Journal of Immunology.

[4]  G. Fantuzzi,et al.  Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  K. Kinoshita,et al.  Deletion of IL-18 receptor ameliorates renal injury in bovine serum albumin-induced glomerulonephritis. , 2008, Clinical immunology.

[6]  E. Petricoin,et al.  Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Michael G. Shields.  Translator's Introduction , 2001 .

[8]  T. Niewold,et al.  Cutting Edge: Autoimmune Disease Risk Variant of STAT4 Confers Increased Sensitivity to IFN-α in Lupus Patients In Vivo1 , 2009, The Journal of Immunology.

[9]  K. Moore,et al.  IFN-gamma limits macrophage expansion in MRL-Fas(lpr) autoimmune interstitial nephritis: a negative regulatory pathway. , 1998, Journal of immunology.

[10]  B. Rollins,et al.  Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. , 1999, The Journal of clinical investigation.

[11]  J. Atkinson,et al.  Rheumatic syndromes associated with complement deficiency , 2003, Current opinion in rheumatology.

[12]  K. Kinoshita,et al.  Blockade of IL-18 Receptor Signaling Delays the Onset of Autoimmune Disease in MRL-Faslpr Mice1 , 2004, The Journal of Immunology.

[13]  V. Kelley,et al.  IL-12 Deficiency in MRL-Faslpr Mice Delays Nephritis and Intrarenal IFN-γ Expression, and Diminishes Systemic Pathology1 , 2003, The Journal of Immunology.

[14]  P. Bossù,et al.  Lymphocytes from Autoimmune MRL lpr/lpr Mice Are Hyperresponsive to IL-18 and Overexpress the IL-18 Receptor Accessory Chain1 , 2001, The Journal of Immunology.

[15]  F. Finkelman,et al.  Differential Contribution of IL-4 and STAT6 vs STAT4 to the Development of Lupus Nephritis1 , 2003, The Journal of Immunology.

[16]  N. Copeland,et al.  Stat4, a novel gamma interferon activation site-binding protein expressed in early myeloid differentiation , 1994, Molecular and cellular biology.

[17]  D. Choubey,et al.  Type-I Interferon Receptor Deficiency Reduces Lupus-like Disease in NZB Mice , 2003, The Journal of experimental medicine.

[18]  R. Wüthrich,et al.  Up-regulation of tubular epithelial interleukin-12 in autoimmune MRL-Fas(lpr) mice with renal injury. , 1997, Kidney international.

[19]  R. Mulligan,et al.  Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[20]  José Miguel Reyes,et al.  Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Minoru Satoh,et al.  Pivotal Role of Stat4 and Stat6 in the Pathogenesis of the Lupus-Like Disease in the New Zealand Mixed 2328 Mice 1 , 2003, The Journal of Immunology.

[22]  J H Lin,et al.  Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[23]  J. Darnell,et al.  Stat3 and Stat4: members of the family of signal transducers and activators of transcription. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Ryffel,et al.  IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. , 1997, Journal of immunology.

[25]  Wentian Li,et al.  STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. , 2007, The New England journal of medicine.

[26]  B. Leber,et al.  Phase II multicenter study of oblimersen sodium, a Bcl‐2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‐cell non‐Hodgkin lymphoma , 2008, British journal of haematology.

[27]  L. Rogge,et al.  Regulation of the IL‐12/IL‐12R axis: a critical step in T‐helper cell differentiation and effector function , 1999, Immunological reviews.

[28]  S. Peng,et al.  Interleukin-18 receptor signaling is not required for autoantibody production and end-organ disease in murine lupus. , 2005, Arthritis and rheumatism.

[29]  J. Kriegsmann,et al.  Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis. , 2002, Arthritis and rheumatism.

[30]  S. Akira,et al.  Defective NK cell activity and Th1 response in IL-18-deficient mice. , 1998, Immunity.

[31]  Annette Lee,et al.  Specificity of the STAT4 Genetic Association for Severe Disease Manifestations of Systemic Lupus Erythematosus , 2008, PLoS genetics.

[32]  A. Theofilopoulos,et al.  Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains , 1978, The Journal of experimental medicine.

[33]  A. Schwarting,et al.  IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. , 1998, Journal of immunology.

[34]  P. Galle,et al.  Interferon- (cid:1) : A Therapeutic for Autoimmune Lupus in MRL- Fas lpr Mice , 2022 .

[35]  C. Dinarello.  Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. , 2006, The American journal of clinical nutrition.

[36]  H. Weiner,et al.  IL-12 Drives IFN-γ-Dependent Autoimmune Kidney Disease in MRL-Fas lpr Mice , 1999, The Journal of Immunology.